UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/561,496	06/09/2006	Marcel Jaspars	ABLE0030US.NP 9320	
26259 LICATA & TY	7590 10/13/200 RRELL P.C.	EXAMINER		
66 E. MAIN ST	REET	DAVIS, ZINNA NORTHINGTON		
MARLTON, NJ 08053			ART UNIT	PAPER NUMBER
			1625	
			NOTIFICATION DATE	DELIVERY MODE
			10/13/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

poreilly@licataandtyrrell.com

	Applicat	ion No.	Applicant(s)	
Office Action Summary		196	JASPARS, MARCEL	
		er	Art Unit	
	Zinna No	orthington Davis	1625	
The MAILING DATE of this comm Period for Reply	unication appears on th	ne cover sheet with the c	correspondence addre	ss
A SHORTENED STATUTORY PERIOD WHICHEVER IS LONGER, FROM THE - Extensions of time may be available under the provisi after SIX (6) MONTHS from the mailing date of this countries. If NO period for reply is specified above, the maximum Failure to reply within the set or extended period for really received by the Office later than three mont earned patent term adjustment. See 37 CFR 1.704(b)	MAILING DATE OF Tons of 37 CFR 1.136(a). In no emmunication. In statutory period will apply and apply will, by statute, cause the apples after the mailing date of this constant.	THIS COMMUNICATION EVENT, however, may a reply be tinularly will expire SIX (6) MONTHS from Explication to become ABANDONE	N. nely filed the mailing date of this commod D (35 U.S.C. § 133).	
Status				
1) Responsive to communication(s)	filed on <u>06 <i>July</i> 2009</u> .			
2a)☐ This action is FINAL .	2b)⊠ This action is	non-final.		
3)☐ Since this application is in condition	•	•		erits is
closed in accordance with the pra	ctice under <i>Ex parte</i> Q	uayle, 1935 C.D. 11, 45	53 O.G. 213.	
Disposition of Claims				
4) Claim(s) <u>28-57</u> is/are pending in t 4a) Of the above claim(s) is 5) Claim(s) is/are allowed. 6) Claim(s) <u>28-57</u> is/are rejected. 7) Claim(s) is/are objected to 8) Claim(s) are subject to res	s/are withdrawn from o			
Application Papers				
9) The specification is objected to by 10) The drawing(s) filed on is/a Applicant may not request that any ol Replacement drawing sheet(s) includ	re: a) accepted or be ojection to the drawing(s) ing the correction is requ	be held in abeyance. See ired if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1	
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim a) All b) Some * c) None of 1. Certified copies of the prior 2. Certified copies of the prior 3. Copies of the certified copies application from the Internative See the attached detailed Office accepted.	ty documents have be ty documents have be es of the priority docum tional Bureau (PCT Ru	en received. en received in Applicati nents have been receive lle 17.2(a)).	on No ed in this National Sta	ge
Attachment(s)		_		
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review Information Disclosure Statement(s) (PTO/SB/0 Paper No(s)/Mail Date 12/19/05. 		4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate	

Application/Control Number: 10/561,496 Page 2

Art Unit: 1625

DETAILED ACTION

1. Claims 28-57 are pending.

- 2. Claims 1-27 have been canceled.
- 3. Based upon the response filed July 6, 2009, the species election is withdrawn.

The claims are examined as a whole.

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 28-57 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the trityl chloride resin as a solid support does not reasonably provide enablement for "all solid supports". The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

In <u>In re Wands</u>, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. § 112, first paragraph, have been described. They are:

- 1. the nature of the invention,
- 2. the state of the prior art,
- 3. the predictability or lack thereof in the art,
- 4. the amount of direction or guidance present,
- 5. the presence or absence of working examples,
- 6. the breadth of the claims,
- 7. the quantity of experimentation needed, and
- 8. the level of the skill in the art.

The Nature of the Invention

The nature of the invention is drawn to claims for preparing 1,3-dialkyl pyridinium

Application/Control Number: 10/561,496 Page 3

Art Unit: 1625

compounds wherein a solid support is used. See claim 28.

The State of the Prior Art

The state of the prior art teaches that solid supports, solid support substrates and methods of using solid support substrates are suitable for use in the production of very large and complex libraries of pure macrocyclic molecules from simple amino acid starting molecules. The macrocycles may have useful pharmaceutical applications.

See WO03/040094 (Walsh et al, Reference BA, cited by the Applicants).

The predictability or lack thereof in the art

The instant claimed invention is highly unpredictable as discussed below:

It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. In re Fisher, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute.

The instantly claimed invention is highly unpredictable since one skilled in the art would recognize that in regards to a process for preparing chemical compounds the clam solid support is not defined.

At page 43-46, Walsh et al. teaches many solid support substrates which are useful in library formation. However, each solid support bound substrate reacts according to the combination of groups.

The amount of direction or guidance present

The direction present in the instant specification is that the compounds of claim

Art Unit: 1625

28 can be prepared by reacting a solid support. The specification is silent and fails to provide guidance as to whether all solid support compounds can form the claimed linear di-substituted pyridinium compounds.

At page 9, lines 4-11 of the specification, the preferred solid support materials are listed.

The presence or absence of working examples

The only presence of a working example is the Scheme 3 on pages 18-19.

There are not other working examples for any solid support material listed in the specification. The breadth of the claims is that the compound of claim 28 can made with the use of any solid support.

The quantity of experimentation needed

The quantity of experimentation needed is undue experimentation. One of skill in the art would need to determine what solid state support would be reacted and how that target substrate would react.

The level of the skill in the art

The level of skill in the art is high. However, due to the unpredictability in the pharmaceutical art, it is noted that each library of solid support bound substrate may react differently. Additionally, applicants have not provided any biological data for the synthesized compounds. Therefore, it is deemed that further research of an unpredictable nature would be necessary to make or use the invention as claimed.

Therefore, in view of the Wands factors and In re Fisher (CCPA 1970) discussed above, to practice the claimed invention herein, a person of skill in the art would have to

Art Unit: 1625

engage in undue experimentation to test which diseases can be treated by the compound encompassed in the instant claims, with no assurance of success.

- 6. The Information Disclosure Statement filed December 19, 2005 has been considered.
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna Northington Davis whose telephone number is 571-272-0682.
- 8. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
- 9. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Zinna Northington Davis/
Zinna Northington Davis
Primary Examiner
Art Unit 1625